Estradiol receptors in breast cancer cells: Associated co-factors as targets for new therapeutic approaches

Steroids

Volumn 77, Issue 12, 2012, Pages 1249-1261

  Renoir, Jack Michel ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

Breast cancer; Comodulators; Estrogen receptors; Therapeutic approaches

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 5 (2 BENZOTHIAZOLYL)THIOMETHYL 4 HYDROXY 3 METHOXYBENZYLIDENECYANOACETAMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; CG 1511; CYCLIN D1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ESTRADIOL; ESTRADIOL RECEPTOR; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; FULVESTRANT; G PROTEIN COUPLED RECEPTOR 30; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HEAT SHOCK PROTEIN 90; KU 398; LETROZOLE; MC 1575; NUCLEAR RECEPTOR COACTIVATOR; NUCLEAR RECEPTOR COREPRESSOR; PANOBINOSTAT; PLERIXAFOR; PROTEIN TYROSINE KINASE INHIBITOR; RALOXIFENE; SARACATINIB; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID RECEPTOR COACTIVATOR 1; TAMOXIFEN; TRASTUZUMAB; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER PATIENT; CELL CYCLE PROGRESSION; CELL MEMBRANE; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MEDIATOR; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MICROARRAY; PROTEIN PHOSPHORYLATION; RECEPTOR DOWN REGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; VASODILATATION;

EID: 84865550686     PISSN: 0039128X     EISSN: 18785867     Source Type: Journal    
DOI: 10.1016/j.steroids.2012.07.019     Document Type: Review

References (200)

1. S. Ali, and R.C. Coombes Endocrine-responsive breast cancer and strategies for combating resistance Nat Rev Cancer 2 2 2002 101 112
2. V.C. Jordan W. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer J Clin Oncol 25 36 2007 5815 5824
3. E.A. Musgrove, and R.L. Sutherland Biological determinants of endocrine resistance in breast cancer Nat Rev Cancer 9 9 2009 631 643
4. C.M. Perou Molecular portraits of human breast tumours Nature 406 6797 2000 747 752
5. T. Sorlie Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 19 2001 10869 10874
6. J.D. Brenton Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 23 29 2005 7350 7360
7. C. Sotiriou, and L. Pusztai Gene-expression signatures in breast cancer N Engl J Med 360 8 2009 790 800
8. J. Kao Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery PLoS One 4 7 2009 e6146
9. R.M. Evans The steroid and thyroid hormone receptor superfamily Science 240 4854 1988 889 895
10. D.J. Mangelsdorf The nuclear receptor superfamily: the second decade Cell 83 6 1995 835 839
11. G.G. Kuiper Cloning of a novel receptor expressed in rat prostate and ovary Proc Natl Acad Sci USA 93 12 1996 5925 5930
12. S. Mosselman, J. Polman, and R. Dijkema ER beta: identification and characterization of a novel human estrogen receptor FEBS Lett 392 1 1996 49 53
13. K. Dahlman-Wright International union of pharmacology. LXIV. Estrogen receptors Pharmacol Rev 58 4 2006 773 781
14. S. Ali, and R.C. Coombes Estrogen receptor alpha in human breast cancer: occurrence and significance J Mammary Gland Biol Neoplasia 5 3 2000 271 281
15. F. Delaunay Functional differences between the amino-terminal domains of estrogen receptors alpha and beta Mol Pharmacol 58 3 2000 584 590
16. G. Lazennec ER beta inhibits proliferation and invasion of breast cancer cells Endocrinology 142 9 2001 4120 4130
17. S. Paruthiyil Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest Cancer Res 64 1 2004 423 428
18. R.J. Pietras, and C.M. Szego Specific binding sites for oestrogen at the outer surfaces of isolated endometrial cells Nature 265 5589 1977 69 72
19. A. Migliaccio Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells Embo J 15 6 1996 1292 1300
20. E.R. Levin Cellular functions of plasma membrane estrogen receptors Steroids 67 6 2002 471 475
21. C.M. Revankar A transmembrane intracellular estrogen receptor mediates rapid cell signaling Science 307 5715 2005 1625 1630
22. N. Heldring Estrogen receptors: how do they signal and what are their targets Physiol Rev 87 3 2007 905 931
23. M. Le Romancer Cracking the estrogen receptor's posttranslational code in breast tumors Endocr Rev 32 5 2011 587 622
24. J.M. Renoir The non-DNA-binding heterooligomeric form of mammalian steroid hormone receptors contains a hsp90-bound 59-kilodalton protein J Biol Chem 265 18 1990 10740 10745
25. B. Segnitz, and U. Gehring Subunit structure of the nonactivated human estrogen receptor Proc Natl Acad Sci USA 92 6 1995 2179 2183
26. W.B. Pratt The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase Annu Rev Pharmacol Toxicol 37 1997 297 326
27. A. Gougelet Estrogen receptor alpha and beta subtype expression and transactivation capacity are differentially affected by receptor-, hsp90- and immunophilin-ligands in human breast cancer cells J Steroid Biochem Mol Biol 94 1-3 2005 71 81
28. N.J. McKenna, R.B. Lanz, and B.W. O'Malley Nuclear receptor coregulators: cellular and molecular biology Endocr Rev 20 3 1999 321 344
29. C.K. Glass, and M.G. Rosenfeld The coregulator exchange in transcriptional functions of nuclear receptors Genes Dev 14 2 2000 121 141
30. N.J. McKenna, and B.W. O'Malley Combinatorial control of gene expression by nuclear receptors and coregulators Cell 108 4 2002 465 474
31. R. Metivier Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter Cell 115 6 2003 751 763
32. M.G. Rosenfeld, and C.K. Glass Coregulator codes of transcriptional regulation by nuclear receptors J Biol Chem 276 40 2001 36865 36868
33. T.J. Peterson The silencing mediator of retinoic acid and thyroid hormone receptor (SMRT) corepressor is required for full estrogen receptor alpha transcriptional activity Mol Cell Biol 27 17 2007 5933 5948
34. D. Chen, S.M. Huang, and M.R. Stallcup Synergistic, p160 coactivator-dependent enhancement of estrogen receptor function by CARM1 and p300 J Biol Chem 275 52 2000 40810 40816
35. P.J. Kushner Estrogen receptor pathways to AP-1 J Steroid Biochem Mol Biol 74 5 2000 311 317
36. G.B. Tremblay Ligand-independent activation of the estrogen receptors alpha and beta by mutations of a conserved tyrosine can be abolished by antiestrogens Cancer Res 58 5 1998 877 881
37. M. Sanchez The hormonal response of estrogen receptor beta is decreased by the phosphatidylinositol 3-kinase/Akt pathway via a phosphorylation-dependent release of CREB-binding protein J Biol Chem 282 7 2007 4830 4840
38. A. Tremblay Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1 Mol Cell 3 4 1999 513 519
39. N. Picard Phosphorylation of activation function-1 regulates proteasome-dependent nuclear mobility and E6-associated protein ubiquitin ligase recruitment to the estrogen receptor {beta} Mol Endocrinol 22 2 2008 317 330
40. A. Tremblay EM-800, a novel antiestrogen, acts as a pure antagonist of the transcriptional functions of estrogen receptors alpha and beta Endocrinology 139 1 1998 111 118
41. M.E. Mendelsohn, and R.H. Karas The protective effects of estrogen on the cardiovascular system N Engl J Med 340 23 1999 1801 1811
42. C. Bouclier Coadministration of nanosystems of short silencing RNAs targeting oestrogen receptor alpha and anti-oestrogen synergistically induces tumour growth inhibition in human breast cancer xenografts Breast Cancer Res Treat 122 1 2010 145 158
43. C. Pequeux Stromal estrogen receptor-alpha promotes tumor growth by normalizing an increased angiogenesis Cancer Res 72 12 2012 3010 3019
44. C.K. Osborne Tamoxifen in the treatment of breast cancer N Engl J Med 339 22 1998 1609 1618
45. S.T. Pearce, and V.C. Jordan The biological role of estrogen receptors alpha and beta in cancer Crit Rev Oncol Hematol 50 1 2004 3 22
46. R.R. Love Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer N Engl J Med 326 13 1992 852 856
47. V.C. Jordan, S. Gapstur, and M. Morrow Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease J Natl Cancer Inst 93 19 2001 1449 1457
48. R.M. Lavinsky Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes Proc Natl Acad Sci USA 95 6 1998 2920 2925
49. C.L. Smith, Z. Nawaz, and B.W. O'Malley Coactivator and corepressor regulation of the agonist/antagonist activity of the mixed antiestrogen, 4-hydroxytamoxifen Mol Endocrinol 11 6 1997 657 666
50. P. Webb Estrogen receptor activation function 1 works by binding p160 coactivator proteins Mol Endocrinol 12 10 1998 1605 1618
51. D.P. McDonnell Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators Recent Prog Horm Res 57 2002 295 316
52. B. Fisher Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14 J Natl Cancer Inst 86 7 1994 527 537
53. Z. Nawaz Proteasome-dependent degradation of the human estrogen receptor Proc Natl Acad Sci USA 96 5 1999 1858 1862
54. A.L. Wijayaratne, and D.P. McDonnell The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators J Biol Chem 276 38 2001 35684 35692
55. V. Marsaud Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor alpha (ERalpha), differentially affect ERalpha extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells Mol Endocrinol 17 10 2003 2013 2027
56. M. Callige, and H. Richard-Foy Ligand-induced estrogen receptor alpha degradation by the proteasome: new actors? Nucl Recept Signal 4 2006 e004
57. V. Duong ERalpha and ERbeta expression and transcriptional activity are differentially regulated by HDAC inhibitors Oncogene 25 12 2006 1799 1806
58. A. Howell Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J Clin Oncol 22 9 2004 1605 1613
59. J.M. Nabholtz Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group J Clin Oncol 18 22 2000 3758 3767
60. H. Mouridsen Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group J Clin Oncol 19 10 2001 2596 2606
61. M. Baum Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial Lancet 359 9324 2002 2131 2139
62. V.G. Kaklamani Pilot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib Breast Cancer Res Treat 132 3 2012 833 842
63. I. Chu The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer Cancer Res 65 1 2005 18 25
64. M. Marino Distinct nongenomic signal transduction pathways controlled by 17beta-estradiol regulate DNA synthesis and cyclin D(1) gene transcription in HepG2 cells Mol Biol Cell 13 10 2002 3720 3729
65. A. Pedram Integration of the non-genomic and genomic actions of estrogen. Membrane-initiated signaling by steroid to transcription and cell biology J Biol Chem 277 52 2002 50768 50775
66. E.R. Levin, and R.J. Pietras Estrogen receptors outside the nucleus in breast cancer Breast Cancer Res Treat 108 3 2008 351 361
67. L. Bjornstrom, and M. Sjoberg Estrogen receptor-dependent activation of AP-1 via non-genomic signalling Nucl Recept 2 1 2004 3
68. K.H. Kim, and J.R. Bender Membrane-initiated actions of estrogen on the endothelium Mol Cell Endocrinol 308 1-2 2009 3 8
69. R.X. Song The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane Proc Natl Acad Sci USA 101 7 2004 2076 2081
70. I. Barone Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway Cancer Res 69 11 2009 4724 4732
71. I. Barone Phosphorylation of the mutant K303R estrogen receptor alpha at serine 305 affects aromatase inhibitor sensitivity Oncogene 29 16 2010 2404 2414
72. J.M. Knowlden Insulin-like growth factor-I receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor Endocrinology 146 11 2005 4609 4618
73. R.X. Song Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer Endocr Relat Cancer 13 Suppl. 1 2006 S3 S13
74. E.J. Filardo Epidermal growth factor receptor (EGFR) transactivation by estrogen via the G-protein-coupled receptor, GPR30: a novel signaling pathway with potential significance for breast cancer J Steroid Biochem Mol Biol 80 2 2002 231 238
75. E.J. Filardo Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF Mol Endocrinol 14 10 2000 1649 1660
76. P. Thomas Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells Endocrinology 146 2 2005 624 632
77. L. Kang Involvement of estrogen receptor variant ER-alpha36, not GPR30, in nongenomic estrogen signaling Mol Endocrinol 24 4 2010 709 721
78. E.J. Filardo, and P. Thomas Minireview: G protein-coupled estrogen receptor-1, GPER-1: its mechanism of action and role in female reproductive cancer. Renal and vascular physiology Endocrinology 153 7 2012 2953 2962
79. E.J. Filardo Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis Mol Endocrinol 16 1 2002 70 84
80. A. Vivacqua G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells Mol Endocrinol 23 11 2009 1815 1826
81. M. Maggiolini, and D. Picard The unfolding stories of GPR30, a new membrane-bound estrogen receptor J Endocrinol 204 2 2010 105 114
82. L. Albanito Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells Endocrinology 149 8 2008 3799 3808
83. R. Lappano MIBE acts as antagonist ligand of both estrogen receptor alpha and GPER in breast cancer cells Breast Cancer Res 14 1 2012 R12
84. J.F. Couse, and K.S. Korach Estrogen receptor null mice: what have we learned and where will they lead us? Endocr Rev 20 3 1999 358 417
85. E.C. Chang Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells Endocrinology 147 10 2006 4831 4842
86. J. Frasor Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome Cancer Res 66 14 2006 7334 7340
87. A. Strom Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D Proc Natl Acad Sci USA 101 6 2004 1566 1571
88. J. Hartman Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts Cancer Res 66 23 2006 11207 11213
89. G. Lazennec Estrogen receptor beta, a possible tumor suppressor involved in ovarian carcinogenesis Cancer Lett 231 2 2006 151 157
90. M. Stettner The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment Mol Cancer Ther 6 10 2007 2626 2633
91. P. Roger Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors Cancer Res 61 6 2001 2537 2541
92. L.P. Stabile Human non-small cell lung tumors and cells derived from normal lung express both estrogen receptor alpha and beta and show biological responses to estrogen Cancer Res 62 7 2002 2141 2150
93. L.G. Horvath Frequent loss of estrogen receptor-beta expression in prostate cancer Cancer Res 61 14 2001 5331 5335
94. E.F. Foley Selective loss of estrogen receptor beta in malignant human colon Cancer Res 60 2 2000 245 248
95. O.I. Vivar Estrogen receptor beta binds to and regulates three distinct classes of target genes J Biol Chem 285 29 2010 22059 22066
96. N. Levy Unliganded estrogen receptor-beta regulation of genes is inhibited by tamoxifen Mol Cell Endocrinol 315 1-2 2010 201 207
97. L. Hodges-Gallagher Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells Breast Cancer Res Treat 109 2 2008 241 250
98. L. Hodges-Gallagher Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells Breast Cancer Res Treat 105 3 2007 297 309
99. W.B. Pratt, and D.O. Toft Steroid receptor interactions with heat shock protein and immunophilin chaperones Endocr Rev 18 3 1997 306 360
100. B.S. Blagg, and T.D. Kerr Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation Med Res Rev 26 3 2006 310 338
101. L. Bouhouche-Chatelier, A. Chadli, and M.G. Catelli The N-terminal adenosine triphosphate binding domain of Hsp90 is necessary and sufficient for interaction with estrogen receptor Cell Stress Chaperones 6 4 2001 297 305
102. B. Segnitz, and U. Gehring The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin J Biol Chem 272 30 1997 18694 18701
103. L. Neckers Heat shock protein 90: the cancer chaperone J Biosci 32 3 2007 517 530
104. G. Chiosis Targeting chaperones in transformed systems-a focus on Hsp90 and cancer Expert Opin Ther Targets 10 1 2006 37 50
105. D. Picard Chaperoning steroid hormone action Trends Endocrinol Metab 17 6 2006 229 235
106. X.M. Yu Hsp90 inhibitors identified from a library of novobiocin analogues J Am Chem Soc 127 37 2005 12778 12779
107. G. Le Bras New novobiocin analogues as antiproliferative agents in breast cancer cells and potential inhibitors of heat shock protein 90 J Med Chem 50 24 2007 6189 6200
108. C. Radanyi Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90) Bioorg Med Chem Lett 18 7 2008 2495 2498
109. M.G. Marcu The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone J Biol Chem 275 47 2000 37181 37186
110. C. Marx Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer Mol Pharmacol 71 6 2007 1525 1534
111. S.A. Onate Sequence and characterization of a coactivator for the steroid hormone receptor superfamily Science 270 5240 1995 1354 1357
112. X.Y. Guan Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11-q13.2 in breast cancer Cancer Res 56 15 1996 3446 3450
113. B.W. O'Malley Coregulators: from whence came these "master genes" Mol Endocrinol 21 5 2007 1009 1013
114. W. Xu A methylation-mediator complex in hormone signaling Genes Dev 18 2 2004 144 156
115. F.J. Fleming Expression of SRC-1, AIB1, and PEA3 in HER2 mediated endocrine resistant breast cancer; a predictive role for SRC-1 J Clin Pathol 57 10 2004 1069 1074
116. E. Myers Associations and interactions between Ets-1 and Ets-2 and coregulatory proteins, SRC-1, AIB1, and NCoR in breast cancer Clin Cancer Res 11 6 2005 2111 2122
117. D.M. Lonard, and B.W. O'Malley Nuclear receptor coregulators: judges, juries, and executioners of cellular regulation Mol Cell 27 5 2007 691 700
118. A. Oh The nuclear receptor coactivator AIB1 mediates insulin-like growth factor I-induced phenotypic changes in human breast cancer cells Cancer Res 64 22 2004 8299 8308
119. M.C. Louie ACTR/AIB1 functions as an E2F1 coactivator to promote breast cancer cell proliferation and antiestrogen resistance Mol Cell Biol 24 12 2004 5157 5171
120. M.I. Torres-Arzayus High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene Cancer Cell 6 3 2004 263 274
121. M.P. Fereshteh The nuclear receptor coactivator amplified in breast cancer-1 is required for Neu (ErbB2/HER2) activation, signaling, and mammary tumorigenesis in mice Cancer Res 68 10 2008 3697 3706
122. L. Qin The AIB1 oncogene promotes breast cancer metastasis by activation of PEA3-mediated matrix metalloproteinase 2 (MMP2) and MMP9 expression Mol Cell Biol 28 19 2008 5937 5950
123. Y. Wang Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1 Mol Endocrinol 25 12 2011 2041 2053
124. S. Minucci, and P.G. Pelicci Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 1 2006 38 51
125. C. Wang Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity J Biol Chem 276 21 2001 18375 18383
126. M.Y. Kim Acetylation of estrogen receptor alpha by p300 at lysines 266 and 268 enhances the deoxyribonucleic acid binding and transactivation activities of the receptor Mol Endocrinol 20 7 2006 1479 1493
127. S.H. Kim Trichostatin A enhances acetylation as well as protein stability of ERalpha through induction of p300 protein Breast Cancer Res 12 2 2010 R22
128. V. Duong Specific activity of class II histone deacetylases in human breast cancer cells Mol Cancer Res 6 12 2008 1908 1919
129. X. Yi Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling Biochem Pharmacol 75 9 2008 1697 1705
130. G. Urbinati Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy Int J Pharm 397 1-2 2010 184 193
131. L. Stimson HDAC inhibitor-based therapies and haematological malignancy Ann Oncol 20 8 2009 1293 1302
132. X. Yang Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition Cancer Res 60 24 2000 6890 6894
133. X. Yang Synergistic activation of functional estrogen receptor (ER)-alpha by DNA methyltransferase and histone deacetylase inhibition in human ER-alpha-negative breast cancer cells Cancer Res 61 19 2001 7025 7029
134. Q. Zhou, P. Atadja, and N.E. Davidson Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation Cancer Biol Ther 6 1 2007 64 69
135. Q. Zhou, P.G. Shaw, and N.E. Davidson Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells Breast Cancer Res Treat 117 2 2009 443 451
136. E.R. Jang The histone deacetylase inhibitor trichostatin A sensitizes estrogen receptor alpha-negative breast cancer cells to tamoxifen Oncogene 23 9 2004 1724 1736
137. R. Margueron Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens J Mol Endocrinol 32 2 2004 583 594
138. R.W. Johnstone Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nat Rev Drug Discov 1 4 2002 287 299
139. R.R. Rosato, and S. Grant Histone deacetylase inhibitors: insights into mechanisms of lethality Expert Opin Ther Targets 9 4 2005 809 824
140. P.A. Marks The clinical development of histone deacetylase inhibitors as targeted anticancer drugs Expert Opin Investig Drugs 19 9 2010 1049 1066
141. S. Thomas, and P.N. Munster Histone deacetylase inhibitor induced modulation of anti-estrogen therapy Cancer Lett 280 2 2009 184 191
142. C. Van Lint, S. Emiliani, and E. Verdin The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation Gene Expr 5 4-5 1996 245 253
143. Y. Sowa Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites Biochem Biophys Res Commun 241 1 1997 142 150
144. R. Margueron Oestrogen receptor alpha increases p21(WAF1/CIP1) gene expression and the antiproliferative activity of histone deacetylase inhibitors in human breast cancer cells J Endocrinol 179 1 2003 41 53
145. P. Marks Histone deacetylases and cancer: causes and therapies Nat Rev Cancer 1 3 2001 194 202
146. C. Palmieri, R.C. Coombes, and D.M. Vigushin Targeted histone deacetylase inhibition for cancer prevention and therapy Prog Drug Res 63 2005 147 181
147. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 9 2006 769 784
148. J.J. Kovacs HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor Mol Cell 18 5 2005 601 607
149. V. Lafarga A novel GRK2/HDAC6 interaction modulates cell spreading and motility Embo J 31 4 2011 856 869
150. Z. Nawaz The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily Mol Cell Biol 19 2 1999 1182 1189
151. S. Ramamoorthy Overexpression of ligase defective E6-associated protein, E6-AP, results in mammary tumorigenesis Breast Cancer Res Treat 132 1 2012 97 108
152. M. Le Romancer Regulation of estrogen rapid signaling through arginine methylation by PRMT1 Mol Cell 31 2 2008 212 221
153. P.Y. Zeng, and S.L. Berger LKB1 is recruited to the p21/WAF1 promoter by p53 to mediate transcriptional activation Cancer Res 66 22 2006 10701 10708
154. Z.G. Zhuang Enhanced expression of LKB1 in breast cancer cells attenuates angiogenesis, invasion, and metastatic potential Mol Cancer Res 4 11 2006 843 849
155. D.G. Hardie AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy Nat Rev Mol Cell Biol 8 10 2007 774 785
156. S. Nath-Sain, and P.A. Marignani LKB1 catalytic activity contributes to estrogen receptor alpha signaling Mol Biol Cell 20 11 2009 2785 2795
157. K.A. Brown LKB1 expression is inhibited by estradiol-17beta in MCF-7 cells J Steroid Biochem Mol Biol 127 3-5 2011 439 443
158. K. Linher-Melville, S. Zantinge, and G. Singh Liver kinase B1 expression (LKB1) is repressed by estrogen receptor alpha (ERalpha) in MCF-7 human breast cancer cells Biochem Biophys Res Commun 417 3 2012 1063 1068
159. K.A. Brown Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase Breast Cancer Res Treat 123 2 2010 591 596
160. L. Taliaferro-Smith LKB1 is required for adiponectin-mediated modulation of AMPK-S6K axis and inhibition of migration and invasion of breast cancer cells Oncogene 28 29 2009 2621 2633
161. B.D. Manning, and L.C. Cantley AKT/PKB signaling: navigating downstream Cell 129 7 2007 1261 1274
162. L. Varricchio Inhibition of estradiol receptor/Src association and cell growth by an estradiol receptor alpha tyrosine-phosphorylated peptide Mol Cancer Res 5 11 2007 1213 1221
163. S. Hiscox Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells Breast Cancer Res Treat 97 3 2006 263 274
164. X.H. Zhang Latent bone metastasis in breast cancer tied to Src-dependent survival signals Cancer Cell 16 1 2009 67 78
165. M.H. Herynk Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells Mol Cancer Ther 5 12 2006 3023 3031
166. S. Hiscox Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer Endocr Relat Cancer 13 Suppl. 1 2006 S53 S59
167. K. Lindberg Estrogen receptor beta represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity Breast Cancer Res 13 2 2011 R43
168. S.A. Wander, B.T. Hennessy, and J.M. Slingerland Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy J Clin Invest 121 4 2011 1231 1241
169. C. Blenkiron MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype Genome Biol 8 10 2007 R214
170. B.D. Adams, H. Furneaux, and B.A. White The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein expression in breast cancer cell lines Mol Endocrinol 21 5 2007 1132 1147
171. X. Yu Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells BMC Cancer 12 2012 29
172. C.M. Klinge MiRNAs and estrogen action Trends Endocrinol Metab 23 5 2012 223 233
173. X. Wu HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition Cancer Res 66 19 2006 9527 9534
174. K. Jin The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway Proc Natl Acad Sci USA 109 8 2012 2736 2741
175. K.A. Holmes Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells Proc Natl Acad Sci USA 109 8 2012 2748 2753
176. A. Hurtado Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen Nature 456 7222 2008 663 666
177. A. Hurtado FOXA1 is a key determinant of estrogen receptor function and endocrine response Nat Genet 43 1 2011 27 33
178. M. Lupien FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription Cell 132 6 2008 958 970
179. F. Balkwill Cancer and the chemokine network Nat Rev Cancer 4 7 2004 540 550
180. A. Freund IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells Oncogene 22 2 2003 256 265
181. I. Bieche CXC chemokines located in the 4q21 region are up-regulated in breast cancer Endocr Relat Cancer 14 4 2007 1039 1052
182. C. Chavey Oestrogen receptor negative breast cancers exhibit high cytokine content Breast Cancer Res 9 1 2007 R15
183. G. Lazennec, and A. Richmond Chemokines and chemokine receptors: new insights into cancer-related inflammation Trends Mol Med 16 3 2010 133 144
184. J.M. Hall, and K.S. Korach Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells Mol Endocrinol 17 5 2003 792 803
185. K. Sauve Positive feedback activation of estrogen receptors by the CXCL12-CXCR4 pathway Cancer Res 69 14 2009 5793 5800
186. D.R. Robinson Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer Nat Med 17 12 2011 1646 1651
187. Y.W. Asmann Detection of redundant fusion transcripts as biomarkers or disease-specific therapeutic targets in breast cancer Cancer Res 72 8 2012 1921 1928
188. L. Nolan Will histone deacetylase inhibitors require combination with other agents to fulfil their therapeutic potential? Br J Cancer 99 5 2008 689 694
189. C.L. Hostetter, L.A. Licata, and J.C. Keen Timing is everything: order of administration of 5-aza 2′ deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity Cancer Lett 275 2 2009 178 184
190. P.N. Munster A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer Br J Cancer 104 12 2011 1828 1835
191. C. Radanyi Tosylcyclonovobiocic acids promote cleavage of the hsp90-associated cochaperone p23 Biochem Biophys Res Commun 379 2 2009 514 518
192. G. Urbinati Liposomal trichostatin A: therapeutic potential in hormone-dependent and -independent breast cancer xenograft models Horm Mol Biol Clin Invest 6 2 2011 215 225
193. D.C. Drummond Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes Clin Cancer Res 11 9 2005 3392 3401
194. V.P. Torchilin Targeted pharmaceutical nanocarriers for cancer therapy and imaging Aaps J 9 2 2007 E128 E147
195. E. Marangoni CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts Br J Cancer 100 6 2009 918 922
196. G. Chiosis, E. Caldas Lopes, and D. Solit Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents Curr Opin Investig Drugs 7 6 2006 534 541
197. D. Audisio Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery ChemMedChem 6 5 2011 804 815
198. H. Zhao Engineering an antibiotic to fight cancer: optimization of the novobiocin scaffold to produce anti-proliferative agents J Med Chem 54 11 2011 3839 3853
199. J.M. Renoir Improved anti-tumoral capacity of mixed and pure anti-oestrogens in breast cancer cell xenografts after their administration by
200. W.R. Harrington Activities of estrogen receptor alpha- and beta-selective ligands at diverse estrogen responsive gene sites mediating transactivation or transrepression Mol Cell Endocrinol 206 1-2 2003 13 22